Armata Pharmaceuticals appoints Brian Varnum as CEO; Todd Patrick resigns but stays as advisor

Armata Pharmaceuticals, Inc.

Brian Varnum, Ph.D. appointed CEO effective August 1, 2021; was previously President and Chief Development Officer.
Todd R. Patrick resigned as CEO as of Aug 1, 2021; continues as board member until next annual meeting and as advisor through Dec 31, 2022.
Patrick to receive base salary of $550K through Dec 2021, then $275K through transition period; target bonus 50% of base.
Varnum receives base salary $500K, target bonus 50%, and option to purchase 125,000 shares vesting over 4 years.
Half of Patrick's unvested stock options and RSUs vest at end of transition period if he serves full term.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Todd R. Patrick

Chief Executive Officer

ARMP · Armata Pharmaceuticals, Inc.

Effective: 2021-08-01
Successor: Brian Varnum
Filed: August 4, 2021, 7:59 PM ET

Todd R. Patrick, who has served as the Company’s CEO since May 2019, resigned as CEO as of August 1, 2021

Appointed

Brian Varnum

Chief Executive Officer

ARMP · Armata Pharmaceuticals, Inc.

Effective: 2021-08-01
Filed: August 4, 2021, 7:59 PM ET

On August 1, 2021, Brian Varnum, Ph.D. was appointed to serve as Chief Executive Officer

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Todd R. Patrick resigned as Chief Executive Officer at Armata Pharmaceuticals, Inc..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

Todd R. Patrick, who has served as the Company’s CEO since May 2019, resigned as CEO as of August 1, 2021

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Brian Varnum was appointed as Chief Executive Officer at Armata Pharmaceuticals, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On August 1, 2021, Brian Varnum, Ph.D. was appointed to serve as Chief Executive Officer

View on SEC.gov

Armata Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-21-100117

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.